JAX compound evaluation: oncology
Under the direction of Dr. Neal Goodwin, JAX preclinical oncology services provide highly customizable in vivo compound evaluation to help customers evaluate novel anticancer therapies. We offer a breadth of technologies that span from traditional xenograft services to advanced humanized mouse models of cancer and offer the flexibility to customize studies and import client-provided animals and cancer cell lines.
- Subcutaneous human tumor xenografts
- Syngeneic tumor grafts
- Orthotopic engraftment
- Endogenous models
- Patient-derived xenograft resource
Subcutaneous human tumor xenografts
- Xenograft models of human cancer to test compound efficacy
- Model: Engraftment of over 60 cell lines subcutaneously in immunodeficient strains
- Readouts: Tumor volume and growth rate
- Sample study: Lung Cancer Xenograft protocol (.pdf)
Syngenic tumor grafts
- Mouse model for melanoma and metastasis
- Model: B16F10 mouse melanoma cells expressing luciferase engrafted in C57BL/6J
- Readouts:
- Tumor volume and growth rate
- Non-invasive bioluminescence imaging to detect metastases
Orthotopic engraftment
- Human tumor grafts in their sites of origin for compound efficacy studies
- Model: Orthotopic engraftment of a variety of luciferase expressing cell lines
- Readout: Non-invasive bioluminescence imaging
- Sample study: Orthotopic prostate tumor study (.pdf)
Endogenous models
- Compound efficacy testing in a range of genetically engineered, endogenous cancer models
- Readouts: Survival, histopathology, tumor size
Patient-derived xenograft resource
- Compound efficacy testing in mice engrafted with patient-derived tumor xenografts
- Established PDX models for many tumor types (lung, brain, pancreas, etc.)
- Readouts: Survival, tumor volume and growth rate, histopathology
- Learn more: PDX resource information
